DDrare: Database of Drug Development for Rare Diseases

11c-pbr28 (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
13	Multiple sclerosis/Neuromyelitis optica	1

6. Parkinson disease [ 2,123 clinical trials, 2,046 drugs, (DrugBank: 324 drugs), 183 drug target genes, 198 drug target pathways]

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,123 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02702102 (ClinicalTrials.gov)	December 2015	3/3/2016	Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies	Imaging Inflammation in Patients With Diffuse Lewy Body Disease	Diffuse Lewy Body Disease;Dementia With Lewy Bodies;Parkinson's Disease Dementia	Drug: 11C-PBR28	William Charles Kreisl	National Institute on Aging (NIA)	Completed	60 Years	N/A	All	5	Phase 2	United States

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04230174 (ClinicalTrials.gov)	February 2020	13/1/2020	Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation	Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation	Multiple Sclerosis	Drug: 11C-PBR28	Massachusetts General Hospital	Genentech, Inc.	Not yet recruiting	18 Years	65 Years	All	24	Phase 4	NULL